Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives $10.80 Average Target Price from Analysts

Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) have earned an average recommendation of “Moderate Buy” from the six ratings firms that are covering the company, Marketbeat reports. One analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $10.80.

Several analysts recently weighed in on RGLS shares. StockNews.com raised shares of Regulus Therapeutics to a “sell” rating in a report on Tuesday, September 17th. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Regulus Therapeutics in a report on Monday, November 11th.

Regulus Therapeutics Trading Up 2.6 %

Shares of NASDAQ RGLS opened at $1.59 on Wednesday. The stock has a market cap of $104.15 million, a P/E ratio of -1.49 and a beta of 1.61. The business’s fifty day simple moving average is $1.53 and its 200-day simple moving average is $1.69. Regulus Therapeutics has a 12-month low of $1.08 and a 12-month high of $3.79.

Regulus Therapeutics (NASDAQ:RGLS) last posted its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.03). On average, equities analysts forecast that Regulus Therapeutics will post -0.88 EPS for the current fiscal year.

Institutional Trading of Regulus Therapeutics

Several institutional investors have recently modified their holdings of RGLS. NEA Management Company LLC purchased a new position in shares of Regulus Therapeutics in the 3rd quarter valued at $10,154,000. Point72 Asset Management L.P. purchased a new position in shares of Regulus Therapeutics during the third quarter worth about $1,403,000. Vanguard Group Inc. grew its holdings in shares of Regulus Therapeutics by 158.4% during the first quarter. Vanguard Group Inc. now owns 740,215 shares of the biopharmaceutical company’s stock worth $2,132,000 after purchasing an additional 453,784 shares during the last quarter. Bank of New York Mellon Corp acquired a new stake in shares of Regulus Therapeutics during the second quarter worth about $352,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in shares of Regulus Therapeutics in the 3rd quarter valued at about $204,000. Hedge funds and other institutional investors own 92.38% of the company’s stock.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.